Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I multiple ascending-dose study of RGLS-4326 in healthy volunteers

Next Previous
Trial Profile

A phase I multiple ascending-dose study of RGLS-4326 in healthy volunteers

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Feb 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RGLS 4326 (Primary)
  • Indications Autosomal dominant polycystic kidney disease
  • Focus Adverse reactions
  • Sponsors Regulus Therapeutics

Most Recent Events

  • 10 Feb 2021 According to a Regulus Therapeutics media release, the Company will use information from the first cohort of the Phase 1b in its plan to address the second set of requirements outlined in the Partial Clinical Hold letter to support studies of extended duration. Regulus plans to discuss its approach to addressing the remaining Partial Clinical Hold requirements with FDA in mid-2021.
  • 15 Oct 2020 According to a Regulus Therapeutics media release, the company plans to use data from the first cohort of phase 1b study, together with data from multiple ascending dose and single ascending dose studies in healthy volunteers as well as the recently completed nonclinical studies, to obtain feedback from the U.S. Food & Drug Administration(FDA) on the acceptability of the company's approach to addressing the second set of FDA requirements to support studies of extended duration in patients.
  • 22 Jul 2020 According to Regulus Therapeutics media release, the company has completed the dosing in this trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top